Bioregenx, INC 10-Q quarterly reports

BioRegenx reports a net loss of $26,415 for Q1 2026 while highlighting substantial doubt regarding its ability to continue as a going concern due to defaults on $522,500 in debt.

BioRegenx reports a significant reduction in net loss for Q3 2025, despite a 22% drop in net sales and ongoing concerns about debt defaults and internal control weaknesses.

BioRegenx, Inc. reports a reduced net loss but faces significant revenue decline and ongoing going concern doubts, with key loans in default and material weaknesses in internal controls.

BioRegenx's Q1 2025 results show a decrease in net sales but a significant reduction in net loss due to decreased operating expenses.

BioRegenx's Q3 2024 report reveals a net loss of $4.65 million, a 39% increase compared to the same period last year, alongside restated financials and identified material weaknesses in internal controls.

BioRegenx, Inc. reports a significant increase in net losses for the second quarter of 2024, driven by decreased sales, increased returns, and higher operating expenses following a merger and product issues.

BioRegenx, Inc. has filed an amended quarterly report for Q1 2024, restating its financials due to a change in auditors and adjustments related to recent acquisitions and a merger.

BioRegenx Inc. reports a net loss of $704,806 for the first quarter of 2024, following a merger and highlighting material weaknesses in internal controls.

BioRegenx, Inc. reports a net loss of $704,806 for the first quarter of 2024, following a merger and experiencing a decrease in revenue compared to the same period last year.